Literature DB >> 10532534

The portosystemic shunt protects liver against ischemic reperfusion injury.

H N Sankary1, D P Yin, A S Chong, L L Ma, L Blinder, J K Shen, P Foster, L P Liu, C Li, J W Williams.   

Abstract

BACKGROUND: The goal of this study was to characterize the importance of splanchnic viscera in liver ischemic reperfusion injury and to enhance the tolerance of liver to warm ischemia injury with portosystemic shunt.
METHODS: The hepatic blood flow of male Sprague Dawley rats was subjected to 45, 60, 120, and 150 min liver warm ischemia with or without portosystemic shunt (splenic-caval shunt). The production of tumor necrosis factor a (TNFa), nuclear factor-kappaB activation, inducible NO synthase (iNOS) expression, and apoptosis were examined.
RESULTS: A total of 67% of rats with 45 min liver warm ischemia (n=6) and 100% of rats with 60 min liver warm ischemia (n=6) died within 1 day. However, all rats with 120 min (n=8) liver warm ischemia in splenic-caval shunt group survived for over 1 day, 6/8 for over 3 days, and 5/8 for over 5 days without significant histological changes of the liver. Serum tumor necrosis factor levels in liver warm ischemic rats were increased, This increase was significantly reversed after portosystemic shunt. After challenge with lipopolysaccharide (1 mg/kg, p.v.), naive rats survived for over 5 days (n=4) with the peak value of rat tumor necrosis factor (240 pg/ml) at 90 min. In contrast, all rats died within one day (n=5) with the peak value of rat tumor necrosis factor a (465 pg/ml) at 45 min after administration of lipopolysaccharide in the rats with liver warm ischemia plus splenic-caval shunt. iNOS expression and nuclear factor-kappaB activation were very strongly increased in the hepatocytes after liver warm ischemia with portosystemic shunt, compared with liver ischemia without portosytemic shunt.
CONCLUSIONS: We conclude that the splanchnic viscera can contribute to liver ischemic reperfusion injury. Portosystemic shunt enhances the tolerance of liver to warm ischemia through the protective role of iNOS and nuclear factor-kappaB (NF-kappaB).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10532534     DOI: 10.1097/00007890-199910150-00010

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  Effect of atrial natriuretic peptide on ischemia-reperfusion injury in a porcine total hepatic vascular exclusion model.

Authors:  Katsumi Kobayashi; Kiyohiro Oshima; Masato Muraoka; Takahiko Akao; Osamu Totsuka; Hisashi Shimizu; Hiroaki Sato; Kazumi Tanaka; Kenjiro Konno; Koshi Matsumoto; Izumi Takeyoshi
Journal:  World J Gastroenterol       Date:  2007-07-07       Impact factor: 5.742

2.  Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury.

Authors:  Danielle G Souza; Adriana C Soares; Vanessa Pinho; Humberto Torloni; Luiz F L Reis; Mauro M Teixeira; Adriana A M Dias; Mauro T Martins
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

3.  Novel in vitro model for studying hepatic ischemia-reperfusion injury using liver cubes.

Authors:  Bernard J DuBray; Kendra D Conzen; Gundumi A Upadhya; Parvathi Balachandran; Jianluo Jia; Brett L Knolhoff; David H Alpers; Thallachallour Mohanakumar; William C Chapman; Christopher D Anderson
Journal:  Surgery       Date:  2012-06-13       Impact factor: 3.982

4.  BH3-only proteins contribute to steatotic liver ischemia-reperfusion injury.

Authors:  Bernard J DuBray; Kendra D Conzen; Gundumi A Upadhya; Kristen L Gunter; Jianluo Jia; Brett L Knolhoff; Thallachallour Mohanakumar; William C Chapman; Christopher D Anderson
Journal:  J Surg Res       Date:  2014-10-22       Impact factor: 2.192

Review 5.  Effects of iNOS in Hepatic Warm Ischaemia and Reperfusion Models in Mice and Rats: A Systematic Review and Meta-Analysis.

Authors:  Richi Nakatake; Mareike Schulz; Christina Kalvelage; Carina Benstoem; René H Tolba
Journal:  Int J Mol Sci       Date:  2022-10-07       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.